QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and ...

The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, it also revealed that its long-term chief executive, Thierry Bernard, will ...

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform ...

Qiagen’s next-generation sequencing tests are already used to look for genetic variants that may shed light on an individual’s specific case of cancer and potential treatment options, but the ...

On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction ...

REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new ...

The LIAISON® LymeDetect® assay is a solution for the early diagnosis of Lyme Borreliosis combining detection of IgG and IgM Antibodies and cellular immunity The test is available in countries ...

Qiagen aims to help scientists and caregivers use biological samples to identify and solve problems related to DNA, RNA, and proteins, which should remain in high demand even after the pandemic, ...

QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.

Capital return to be conducted through synthetic share repurchase // Return of up to $300 million – maximum approved by shareholders in 2023 – designed to enable efficient return of cash to ...

Sackers reaffirmed full-year outlook for total net sales growth of about 4% to 5% at constant exchange rates, with core portfolio expected to grow 5% to 6% CER. Adjusted EPS guidance was raised to ...